How to buy an anti-bacterial tablet and the difference between generics and brand names
A couple of years ago, a pharmaceutical company named Baxter Pharmaceuticals filed a patent application for a drug to treat antibiotic-resistant infections.
The product, dubbed MerciSuite, would make it easier to find antibiotics in stores and online, and would allow consumers to get the drugs they need at pharmacies.
The company says it would help reduce antibiotic use in the United States.
Now, Baxter says it’s been granted an important patent covering Mercisuite’s antibacterial properties.
“It’s one of the most important patents we’ve had,” says Bill DeHaan, president and CEO of Baxter Pharmaceutical.
“We’re pretty excited about it.”
Baxter’s patent application covers Merci Suite’s ability to bind with the surface of a bacterial cell.
It describes a process by which the antibiotic binds to a surface protein, which in turn binds to an enzyme that can produce a molecule of antibiotic.
In a patent filing from 2013, Baxter describes a new kind of antibacterial peptide, called a peptide-protein complex, which allows for a wide variety of antibiotics to bind to a single molecule of bacteria, a process called binding.
The patent describes how the peptide can bind to the surface proteins of bacteria and the enzyme that converts the bacteria’s natural antimicrobial peptide into antibiotic peptide.
Baxter’s claim of binding between Merci Suite and a bacterial enzyme is novel.
The new technology could allow Baxter to create new antibacterial products with a lower cost, DeHaans said in an interview with CBC News.
Baxter is currently working with other companies on developing antibacterial drugs.
In addition to Baxter, other companies that have applied for patents covering the same antibacterial technology include Johnson & Johnson and Merck.
“There are many, many companies that are developing antibacteria products,” DeHaant said.
It’s going be able to do a lot of things.” “
The thing that is exciting about this patent is that it’s going to help create a whole new class of antibacterials.
It’s going be able to do a lot of things.”
It’s important for consumers to understand how the antibiotic they buy can affect how the bacteria they are using are treated, says Tom Nussle, CEO of the Canadian Antibiotic Alliance, an industry trade group.
“That’s really important, because if you have an antibiotic that’s causing bacteria to kill each other, then the antibiotic that is being used will kill the other bacteria that are causing that to happen,” he said.
Antibiotics should be used only by people who have a clean hands and mouths, he said, and should be kept away from animals and people who don’t have proper hygiene.
“If you are using a product that is not going to do what it is supposed to do, then you should probably get an antibiotic,” Nussles said.
The antibacterial activity of a particular antibiotic is a key factor when choosing an antibacterial product, and this patent will help manufacturers better understand how to test the effectiveness of a specific antibiotic.
Baxter said the antibiotic it is developing is a new one called MecsuSuite and it has the potential to be used for a range of other products.
The drug will be used to treat infections of the digestive tract, urinary tract, and skin, and to prevent the growth of bacteria.
Baxter says the antibacterial effect of MerciSUite will also be seen in its other antibacterial tablets.
Baxter has said it plans to release new antibacterial tablets soon.